Compound that specifically binds to KIR3DL2 for use in the treatment of peripheral T cell lymphoma
US12084498B2 · kind B2 · utility
0Cited by
20References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 29, 2021 |
| Grant date | Sep 10, 2024 |
| Priority date | — |
| Expiry date | Nov 26, 2041 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/70503
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.